ArticleFrontiers in pharmacology2025

Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as first-line treatment for advanced squamous non-small cell lung cancer.

Xiaoyan You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.